The American Journal of Managed Care1 天
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...
Pharmaceutical Technology3 天
Cabometyx by Exelixis for Salivary Gland Cancer: Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...